

Hansa Medical

- PRESS RELEASE -
April 6, 2016

Proposed chairman Ulf Wiinberg buys shares in Hansa Medical

Ulf Wiinberg has purchased 75,000 shares in Hansa Medical AB (publ) during April 5-6, 2016. He has been nominated by the company's nomination committee as new chairman of the board. The annual general meeting will be held on May 11.

About Hansa Medical AB

Hansa Medical is a biopharmaceutical company focusing on novel immunomodulatory enzymes. The lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Additional projects focus on development of new antibody modulating enzymes, as well as HBP, a diagnostic biomarker for prediction of severe sepsis at emergency departments that is already introduced on the market. The company is based in Lund, Sweden. Hansa Medical's share (ticker: HMED) is listed on Nasdaq Stockholm's main market.

For further information, please contact:

Göran Arvidson, CEO Hansa Medical AB

Mobile: +46 70-633 30 42

E-mail: goran.arvidson@hansamedical.com

www.hansamedical.com

The information in this press release is disclosed pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was released for public disclosure on April 6, 2016 at 15.00 CET.